Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index (COMETI P2)
COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Sponsor: Janssen Diagnostics, LLC
Listed as NCT01701050, this observational or N/A phase trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by Janssen Diagnostics, LLC, it has been updated 13 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Mar 2017 — Aug 2017 [monthly]
Completed NA
-
Feb 2017 — Mar 2017 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Diagnostics, LLC
For direct contact, visit the study record on ClinicalTrials.gov .